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ARTICLE
E2F4 regulates transcriptional activation
in mouse embryonic stem cells independently
of the RB family
Jenny Hsu1,2, Julia Arand 1,2, Andrea Chaikovsky1,2, Nancie A. Mooney3, Janos Demeter3, Caileen M. Brison4,
Romane Oliverio1,2, Hannes Vogel1,5, Seth M. Rubin4, Peter K. Jackson3 & Julien Sage 1,2
E2F transcription factors are central regulators of cell division and cell fate decisions. E2F4
often represents the predominant E2F activity in cells. E2F4 is a transcriptional repressor
implicated in cell cycle arrest and whose repressive activity depends on its interaction with
members of the RB family. Here we show that E2F4 is important for the proliferation and the
survival of mouse embryonic stem cells. In these cells, E2F4 acts in part as a transcriptional
activator that promotes the expression of cell cycle genes. This role for E2F4 is independent
of the RB family. Furthermore, E2F4 functionally interacts with chromatin regulators asso-
ciated with gene activation and we observed decreased histone acetylation at the promoters
of cell cycle genes and E2F targets upon loss of E2F4 in RB family-mutant cells. Taken
together, our findings uncover a non-canonical role for E2F4 that provide insights into the
biology of rapidly dividing cells.
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Regulation of the cell cycle is a basic biological process thatensures the function and health of the entire organism. Theproliferation of stem/precursor cells, the terminal differ-
entiation of post-mitotic cells, and the establishment and main-
tenance of quiescent and senescent cells all require proper cell
cycle regulation and are all critical for proper tissue development
and homeostasis (reviewed in1). Aberrant cell cycle progression is
linked to tumorigenesis, and blocks in cell cycle entry are linked
to aging and age-related diseases (reviewed in2,3). Thus, a better
understanding of cell cycle principles, including in stem cells,
remains an important aspect of understanding human biology
and improving human health.
The RB/E2F module is a well-established regulator of the G1/S
transition of the cell cycle. It consists, in part, of RB and its family
members p107 and p130, and the E2F family of transcription
factors. The “classical” E2Fs (E2F1, E2F2, E2F3a, E2F3b, E2F4,
and E2F5) can physically associate with the RB family proteins,
which regulate their activity (reviewed in4–6). These E2Fs can be
further subdivided into canonical “repressors” (E2F3b, E2F4,
E2F5) and “activators” (E2F1, E2F2, E2F3a) depending on their
purported activity at the promoters of cell cycle genes. While
“repressor” E2Fs form complexes with the RB family proteins to
inhibit the expression of cell cycle genes at the G1/S transition,
“activator” E2Fs upregulate the expression of these genes to
promote cell cycle entry. Binding to RB inhibits the transactiva-
tional potential of the activator E2Fs. Thus, this interplay between
the “repressor” and “activator” E2Fs mediated by their association
with the RB family proteins, is thought to ensure proper cell cycle
progression4. A vast majority of human tumors carry alterations
that inactivate the function of the RB family, and therefore
characterizing the effects of this inactivation is of central biolo-
gical importance. However, we still do not fully understand the
molecular and cellular roles of the module components, including
their interactions with each other and with context-dependent
cofactors (reviewed in7).
The most ubiquitously and strongly expressed E2F family
member, E2F4, has long been classified as a “repressor” E2F
that silences the expression of cell cycle genes during G0 and
G1 in conjunction with the RB family proteins (reviewed in8).
E2F4 is thought to rely on the RB family proteins for translo-
cation into the nucleus in G0/G1 as well as for repression of cell
cycle genes9. During S phase, hyperphosphorylation of the RB
family proteins prevents their binding to E2F4, and E2F4 is
exported to the cytoplasm10, allowing activator E2Fs, which
possess a nuclear localization signal, to promote the tran-
scription of cell cycle genes. Although E2F4 contains a trans-
activation domain similar to that of activator E2Fs, binding to
RB family members blocks this domain. The co-incidence of
E2F4 release from RB family members and its export from the
nucleus supports a model in which E2F4 does not act as a
transcriptional activator11,12.
Despite this well-established model, evidence from over-
expression studies and in specific cell types such as fast-cycling
intestinal cells suggests that E2F4 has the ability to activate
genes and/or the proliferation of cells in some contexts (e.g.13–17).
In multiciliated cells, E2F4 and its close homolog E2F5
can promote the expression of genes involved in centriole
assembly and ciliogenesis18–20. However, these observations and
other recent studies21,22 often rely on correlative analyses in cells
with loss of E2F4 function or E2F4 overexpression. For instance,
E2f4 knockout mice exhibit a reduced or absent crypt region and
poorly developed villi in the intestines, which may suggest a pro-
proliferative role for E2F423 but might also be due to develop-
mental defects and general poor health24. Overall, whether E2F4
can function as a transcriptional activator in physiological con-
texts remains largely unexplored.
Mouse embryonic stem cells (mESCs) display little to no G1
phase but express surprisingly high levels of E2F4 (reviewed in25).
This observation led us to examine the consequences of E2F4 loss
in these cells. We found that E2F4 normally promotes the
expansion of mESCs in part by directly activating the transcrip-
tion of cell cycle genes. We also found that this role for E2F4 is
independent of the RB family and may rely on the activity of
histone acetyltransferases. These data provide conclusive evidence
that E2F4 can function as a transcriptional activator in a biolo-
gically relevant context.
Results
E2F4 is highly expressed in mouse ES cells. mESCs are rapidly
dividing cells in which the RB family proteins are constitutively
hyperphosphorylated due to constitutive Cyclin-dependent
kinase (Cdk) activity25. Thus, the repressor E2Fs, including
E2F4, are expected to be inactive in mESCs, with either low
expression levels or largely cytoplasmic localization. However, we
noticed that E2F4 is the most highly expressed E2F in mESCs
both at the RNA (ENCODE data26, Supplementary Fig. 1a) and
the protein level27 (Supplementary Fig. 1b). Furthermore, pre-
vious chromatin immunoprecipitation (ChIP) studies revealed
that ectopically-expressed E2F4 can regulate numerous loci in the
genome of mESCs, including genes coding for histones28, often in
conjunction with the cell cycle activator c-MYC29, suggesting that
E2F4 can be nuclear and access chromatin in mESCs. An analysis
of these ChIP datasets showed enrichment for biological pro-
cesses normally regulated by the E2Fs (cell cycle, DNA repair, and
metabolism) (Supplementary Fig. 1c, d). These observations led
us to further investigate E2F4 activity in mESCs.
E2F4 is not required for the self-renewal of mouse ES cells. We
generated E2F4 knockout (E2F4KO) mESCs using CRISPR/Cas9
with independent single-guide RNAs (sgRNAs) to target exons 1
and 3 of the E2f4 locus in J1 mESCs (Supplementary Fig. 2a).
E2F4 knockout in independently-derived clonal lines was con-
firmed at the protein level and by sequencing of the allelic regions
around the sgRNA targets (Supplementary Fig. 2b,c). Control
clones included mESC clones that had been transfected with the
same Cas9 and sgRNA system but retained E2F4 protein (WT,
wild-type), as well as mESC clones transfected with Cas9 only (see
Methods).
Repressor complexes comprised of E2F4 and RB family
proteins have been shown to control the expression of
pluripotency programs30. We therefore first sought to determine
whether loss of E2F4 affects the pluripotency of mESCs. E2F4KO
and WT mESC lines were morphologically indistinguishable and
could be kept in culture over 20 passages. Low-density plating
followed by staining for alkaline phosphatase (AP), a marker of
undifferentiated mESCs, revealed no significant difference
between the clonogenic ability of E2F4KO and WT mESCs, even
at high passage numbers (Supplementary Fig. 3a-c). Both
E2F4KO and WT mESCs could be differentiated into embryoid
bodies that gave rise to neurons (Supplementary Fig. 3d). In
addition, both E2F4KO and WT mESCs gave rise to teratomas
in nude mice with evidence of multi-lineage differentiation
(Supplementary Fig. 3e). Thus, E2F4 does not critically maintain
the self-renewal or pluripotency of mESCs and does not play a
critical role in the ability of these cells to differentiate in the
contexts analyzed.
E2F4 is required for the optimal growth of mouse ES cell
populations. In prolonged culture, we noticed that E2F4KO
mESCs grow more slowly compared to their WT counterparts
(Supplementary Fig. 3a). In addition, E2F4KO mESCs formed
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significantly smaller AP-positive (AP+) colonies when plated at
low density (Fig. 1a, b). We observed the same phenotype with
E2F4KO mESCs from a different line (R1 mESCs) that we gen-
erated using the same CRISPR/Cas9 approach (Supplementary
Fig. 4a, b). The difference could also be observed when mESCs
were plated in 2i media (Supplementary Fig. 4c), which supports
a more naïve/ground pluripotent state31. The formation of
smaller AP+ colonies was not due to an increased tendency of
E2F4KO mESCs to differentiate at low density, as the area stained
by Giemsa (which labels all cells) was equivalent to the area of AP
staining (Fig. 1c). Moreover, the decrease in colony size was not
due to a decrease in cell size, as E2F4KO mESCs were larger than
WT mESCs as determined by flow cytometry (Fig. 1d), but to a
decrease in the number of cells within the colonies (Fig. 1e).
The loss of all three RB family proteins (RB, p107, and p130),
which normally repress the G1/S transition in a complex with
E2F4, has little or no reported effect on the expansion of
mESCs32,33. These data showing that E2F4 is required for the
normal expansion of mESCs suggested that E2F4 may have new
roles in mESCs beyond acting as a repressor of the G1/S
transition.
E2F4 drives the cell cycle progression of mouse ES cells. We
next analyzed the cell cycle structure and cell survival of WT and
E2F4KO mESCs. E2F4KO populations had a greater percentage
of cells in G1 and a smaller percentage of cells in S phase (Fig. 2a
and Supplementary Fig. 5a). To probe for possible defects at
specific cell cycle stages in the E2F4KO cells, we synchronized
mESCs in G0 using the Myc inhibitor 10058-F4, which can arrest
mESCs in G0 without compromising their self-renewal and
pluripotency34, and measured the kinetics of cell cycle entry upon
release from inhibition. Both WT and E2F4KO mESCs were
similarly able to exit the cell cycle and maintain viability after 48 h
of Myc inhibition, as recently described for WT mESCs, while RB
family TKO mESCs are unable to arrest upon Myc inhibition
(Fig. 2b and Supplementary Fig. 5b). Upon inhibitor withdrawal
and cell cycle re-entry, the percentage of G0/G1 cells decreased
more slowly in the E2F4KO mESC populations, while the per-
centage of S phase cells increased more slowly as well (Fig. 2c).
These results suggest that E2F4 is a positive regulator of pro-
gression through the G1/S phase of the cell cycle in mESCs. In
addition to cell cycle defects, we observed decreased viability in
low-density assays for E2F4KO mESCs compared to their con-
trols (Fig. 2d and Supplementary Fig. 5c), which may contribute
to the diminished expansion of E2F4KO mESCs in culture.
E2F4 mutant mouse ES cells have lower expression of cell cycle
genes. To identify the molecular changes that underlie the defects
we observed in E2F4KO mESCs, we performed an RNA-Seq
analysis of WT and E2F4KO mESCs. This analysis revealed that
1842 and 2155 genes were significantly downregulated and
upregulated, respectively, upon loss of E2F4 (adjusted p-value <
0.05, absolute log2(fold-change) >0.5) (Fig. 3a, Supplementary
Fig. 6a and Supplementary Data 1). By Gene Set Enrichment
Analysis (GSEA), the downregulated genes enriched for a larger
number of hallmark gene sets than the upregulated genes. Such
hallmark gene sets include MYC and E2F targets and other genes
involved in cell cycle pathways (Supplementary Fig. 6b). The
proximal regulatory regions of the downregulated genes were also
enriched for E2F binding sites (Supplementary Fig. 6c and Sup-
plementary Data 2-3).
We next integrated our RNA-Seq datasets with existing ChIP
datasets of ectopically-expressed E2F4 in mESCs29. 697 out of
1842 downregulated genes and 409 out of 2155 upregulated genes
overlapped with E2F4 direct targets from the ChIP data (Fig. 3b
and Supplementary Data 4). While the overlap between the
downregulated genes and the ChIP datasets was significant (p=
0.0069), the overlap between the upregulated genes and the ChIP
datasets was the same as would be expected from two random
gene sets of the same size (p= 0.99), suggestive of an enrichment
for direct E2F4 targets in the downregulated group. Down-
regulated genes bound by E2F4 were enriched for biological
processes that involve metabolic, biosynthetic, and cell cycle
genes (Fig. 3c). Notably, RT-qPCR analysis of canonical E2F
targets (Dhfr, Mcm3, Pcna, Ccne2) in an independent passage of
E2F4KO and WT mESCs confirmed that the expression of these
genes is downregulated upon loss of E2F4 expression (Fig. 3d).
Upregulated genes are enriched for metabolic processes as well,
and also for genes involved in development and cellular adhesion
(Supplementary Fig. 6d).
These gene expression and ChIP data indicate that E2F4 serves
as both a direct activator and a direct repressor of gene programs
in mESCs, with a more prominent role as an activator. This
includes a direct role as an activator of genes implicated in cell
cycle progression that are usually upregulated by the canonical
activator E2Fs in other cell types.
E2F4 activator function relies on its transactivation domain.
All of the E2Fs that physically interact with the RB family pro-
teins, including E2F4, have a C-terminal transactivation domain
(Fig. 4a). However, E2F4 also contains a dual nuclear export
signal, and its translocation into the nucleus relies on RB family
binding, which inhibits the transactivation domain9,11,12,35,36.
Based on our data, we sought to further test the possibility that
E2F4 may act as a direct transcriptional activator in mESCs. To
this end, we expressed wild-type and mutant forms of E2F4 (all
fused to GFP) in WT and E2F4KO mESCs at levels similar or
lower to endogenous E2F4, and analyzed the ability of these
constructs to rescue colony size and gene expression (Fig. 4a, b
and Supplementary Fig. 7a). GFP-T360 harbors a truncation of
the transactivation domain and is incapable of inducing target
gene expression36. GFP-DBD harbors point mutations in the
DNA binding domain that disrupt interactions with the E2F4
consensus binding sequence and the DP family proteins37. The
exogenous wild-type E2F4 and truncated GFP-T360 proteins
localized to the nucleus, but the GFP-DBD mutant was less
present in the nucleus (Supplementary Fig. 7b). Importantly,
ectopic expression of E2F4 in E2F4KO mESCs restored the size of
AP+ colonies to wild-type levels and increased cell count after
one week, while expression of the mutants had no effect (Fig. 4c,
d). Expression of cell cycle genes was similarly rescued to wild-
type levels by wild-type E2F4 (Fig. 4e), but not by the E2F4
mutants. Notably, expression of the E2F4 constructs in WT
mESCs did not significantly impact cell proliferation and the
expression of cell cycle genes, suggesting that these constructs do
not have nonspecific effects that may affect the results of the
rescue experiments. GFP-T360 is expressed at slightly higher
levels than the other constructs in WT mESCs and is associated
with a trend toward increased expression of cell cycle genes, likely
due to the displacement of endogenous repressor complexes from
the promoters of these genes. However, the change in gene
expression was not significant for the majority of genes tested.
The inability of the overexpressed E2F4 mutants to rescue these
phenotypes supports the idea that E2F4 serves as a direct acti-
vator of target genes, including cell cycle genes, in mESCs.
E2F transcription factors often compensate for each other. We
found no evidence of increased transcription for E2F1/2/3, but
observed a significant increase in the binding of E2F1 to canonical
cell cycle genes in E2F4KO mESCs (Supplementary Fig. 8a, b),
supporting the idea of at least partial compensation. However, we
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10901-x ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2939 | https://doi.org/10.1038/s41467-019-10901-x | www.nature.com/naturecommunications 3
a b
G1 S
G2
/M
0
10
20
30
40
50
60
70
80
90
%
 C
el
ls
WT
KO
p = 0.02
p = 0.007 2i media
WT and KO
G0
(then release)
+10058-F4
(Myci)
48 h
c
Hours post-release
from G0
2N
Ch
an
ge
 in
 %
 c
el
ls
–25
–20
–15
–10
–5
0
S-phase
WT
KO
0
6 8 10 12 6 8 10 12
5
10
15
20
25
Ch
an
ge
 in
 %
 c
el
ls
Hours post-release
from G0
WT
KO
d
p = 0.05
p = 0.06
WT KO TK
O
0
10
20
30
40
50
60
%
 C
el
ls 
wi
th
 2
N
DN
A 
co
nt
en
t
24 h DMSO
24 h Myci
48 h DMSO
48 h Myci
p = 0.002
p = 0.01
p = 0.009
p = 0.01
WT
1
WT
2
KO
1
KO
2
KO
3
KO
4
0
20
40
60
80
%
 L
ive
 c
el
ls
p = 0.01
Fig. 2 E2F4 mutant mouse ES cells are defective for cell cycle and cell survival. a Quantification of the percentage of cells in G1, S, and G2/M phases based
on BrdU/PI FACS analysis (unpaired t-test; n= 2 biological replicates with 2 wild-type (WT) and 4 E2F4KO (KO) clones), performed after 4 days of low
density plating. b Schematic of synchronizing mESCs in G0 using the Myc inhibitor (Myci) 10085-F4 (left), and quantification of the percentage of cells in
G0/G1 in WT, E2F4KO (KO), and RB family triple knockout (TKO) populations at 24 and 48 h of treatment (unpaired t-test; n= 2–3 biological replicates
with 2 clones of each genotype). c Quantification of the percentage of arrested and cycling cells post-release from Myci. Cell cycle structure was measured
with BrdU/PI staining 6, 8, 10, and 12 h after withdrawal of Myci from the media (unpaired t-test was performed with all individual data points from n= 3–4
biological replicates with 1–2 clones of each genotype). d Quantification of the percentage of AnnexinVneg/PIneg cells (live cells) in WT and E2F4KO
populations 4 days after low density plating (unpaired t-test; n= 3 biological replicates per clone). Data shown as the mean and standard error of the mean
WT KO
Br
ig
ht
fie
ld
Al
ka
lin
e
ph
os
ph
at
as
e
a
WT
1
WT
2
KO
1
KO
2
KO
3
KO
4
0
20
40
60
80
100
p = 0.001
Co
lon
y s
ize
 a
re
a
(A
P+
) (p
ixe
l2 )
WT
1
WT
2
KO
1
KO
2
KO
3
KO
4
0
20
40
60
80 AP
Giemsa
Co
lon
y s
ize
ar
ea
 (p
ixe
l2 )
WT
1
WT
2
KO
1
KO
2
KO
3
KO
4
0
25,000
50,000
75,000
100,000
125,000
150,000
p = 0.0002
Re
la
tiv
e 
ce
ll s
ize
 
(m
ed
ian
 flu
ore
sc
en
ce
)
WT
1
WT
2
KO
1
KO
2
KO
3
KO
4
0
1
2
3
4
5
6
7
p = 0.0002
Ce
ll n
um
be
r (×
 10
6 )
b
c d e
Fig. 1 Loss of E2F4 leads to defects in mouse ES cell growth. a Representative brightfield images (scale bar, 400 µm) and alkaline phosphatase (AP)
staining (wells from a 6-well plate are shown) of wild-type (WT) and E2F4KO (KO) colonies one week after plating single cells (n > 10 assays per
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(undifferentiated cells) versus Giemsa staining (all cells) in an independent set of colonies (n= 3 biological replicates per clone) (no significant
differences). d Size of WT and E2F4KO individual cells as estimated by forward scatter in flow cytometric analysis (unpaired t-test; n= 2 biological
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were unable to test whether loss of E2F1 would enhance the
phenotypes observed in E2F4KO cells due to the rapid loss of
E2F1 mutant mESC clones (Supplementary Fig. 8c).
The function of E2F4 in mouse ES cells is RB family-
independent. RB family proteins are hyperphosphorylated and
inactive in mESCs32, suggesting that the function of E2F4 in this
context may be in part RB family-independent. To test this idea,
we knocked out E2F4 in RB family TKO mESCs to generate
E2f4−/−;Rb−/−;p130−/−;p107−/− (quadruple knockout, QKO)
mESCs (Supplementary Fig. 2d, e). Similar to its effects in WT
mESCs, loss of E2F4 led to smaller AP+ colonies with fewer cells
in QKO MESCs compared to TKO controls (Fig. 5a–c).
Accordingly, loss of E2F4 in TKO mESCs led to a greater per-
centage of QKO mESCs in G1 and a smaller percentage in S
phase (Fig. 5d), as well as decreased viability (Fig. 5e).
The complete absence of the RB family proteins had no effect
on the ability of E2F4 to translocate into the nucleus in mESCs
(Fig. 6a, and Supplementary Fig. 9 for loading controls). In
comparison to mouse embryonic fibroblasts (MEFs), WT and
TKO mESCs have a relatively lower percentage of nuclear E2F4;
however, the absolute amount of nuclear E2F4 in mESCs is
similar to that of quiescent MEFs, where E2F4 is expected to be
predominantly bound to chromatin to silence cell cycle genes. In
addition, loss of RB family proteins did not affect the binding of
E2F4 to the promoter region of canonical cell cycle genes in
mESCs (Fig. 6b). Furthermore, RNA-Seq and RT-qPCR analyses
of TKO and QKO mESCs showed a significant overlap between
downregulated and upregulated genes and their cellular functions
with data from the WT and E2F4KO comparison (Fig. 6c, d,
Supplementary Fig. 6e, and Supplementary Data 5).
These genetic experiments demonstrate that a large part of the
cellular and molecular phenotypes due to loss of E2F4 in mESCs
is independent of the RB family. These observations are
consistent with the hyperphosphorylation of RB family proteins
in mESCs and a lack of physical interaction between these
proteins and E2F4. Notably, some of the repressor activity of
E2F4 in mESCs does not require the RB family. Similarly, direct
binding to and activation of some canonical cell cycle genes by
E2F4 is also independent of the RB family.
E2F4 activates transcription with chromatin modifying factors.
The identification of RB family-independent roles for E2F4 in
mESCs suggested that E2F4 might participate in novel, RB
family-independent protein complexes that can contribute to
gene regulation. To test this hypothesis and to identify novel
cofactors that might allow E2F4 to control transcriptional pro-
grams in the absence of functional RB family proteins, we
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expressed a GFP- and S-tagged (localization and affinity pur-
ification tag, LAP-tag)38 lentiviral E2F4 construct in TKO mESCs,
pulled down the E2F4 protein, and performed mass spectrometry
on the eluted fraction (Fig. 7a, b). This approach revealed 108
candidate interactors (Supplementary Data 6). We performed the
same experiment in RPE cells, human somatic cells with a slower
cell cycle structure and active RB. E2F4 bound to known partners,
including RB and members of the DREAM repressor complex39
in RPE cells (Supplementary Data 6) and bound to the DP family
proteins similarly in both cell types (Supplementary Data 7).
Strikingly, 95 of the 108 candidate E2F4 interactors in TKO
mESCs were specific to mESCs, and a number of these factors are
not reported to associate with any of the E2Fs (Supplementary
Fig. 10a, b and Supplementary Data 6). Some post-translational
modifications on E2F4 were different between the two cell types
but the biological significance of these modifications remains
unclear (Supplementary Data 8).
A GO term analysis for the mESC-specific interactors
identified an enrichment for nuclear and DNA binding
complexes, including components of the MLL1 and SAGA
complexes involved in transcriptional regulation and the MutS-
alpha complex involved in DNA repair (Fig. 7c). Members of
chromatin modifying complexes, such as HCF-1, WDR5, and
TRRAP, are known to contribute to the transcriptional activation
of E2F targets or cell cycle genes in certain contexts36,40,41. We
validated through co-IP that E2F4 binds to HCF-1 and YEATS2
(a member of the ATAC histone acetyltransferase complex42)
robustly and specifically in TKO mESCs, while binding of E2F4 to
DREAM complex members (LIN54 and LIN9) was specific to
RPE cells, and binding of E2F4 to DP-1 was similarly robust
between the two cell types (Fig. 7d).
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Based on these observations, we hypothesized that mESC-
specific interactors may serve as co-activators of E2F4 to activate
the transcription of E2F targets in mESCs. We performed rescue
experiments in E2F4KO mESCs using a previously described
mutant form of E2F4 with point mutations that abrogate binding
to HCF-140. Overexpression of this HCF-1 binding domain
mutant form of E2F4 resulted in a phenotype similar to cells
expressing wild-type E2F4, when compared to cells expressing the
T360 truncation of E2F4 (which behaves similar to a GFP-
expressing control—Fig. 4d) (Supplementary Fig. 11a). Over-
expression of a form of E2F4 harboring mutations within the RB
family binding domain (see Methods) was similarly able to rescue
cell proliferation when compared to the truncation mutant, as
expected based on our observations in TKO mESCs (Supple-
mentary Fig. 11a)40,43. These observations suggest that the
interaction between E2F4 and HCF-1 is not absolutely required
for E2F4 to function as a transcriptional activator in mESCs, and
that multiple activator complexes may contribute to this role.
The p300 and CBP (CREB-binding protein) proteins were not
identified in the mass spectrometry analysis. However, they
constitute an important family of acetyltransferases involved in
the regulation of gene expression and cell proliferation, including
the regulation of targets of activator E2Fs44–46. We examined
binding of purified recombinant E2F4 transactivation domain to
three commonly accessed protein interaction domains in CBP
(KIX, TAZ1, and TAZ2). Using isothermal titration calorimetry,
we observed the most robust binding signal using TAZ1 (which
constitutes an interaction site for a number of transcription
factors47) (Supplementary Fig. 11b and data not shown). These
data further support the idea that E2F4 can directly recruit
transcriptional activators, similar to activator E2Fs.
To further investigate the mechanisms by which E2F4 may act
as a direct activator of transcription independently of the RB
family, we performed ChIP-seq assays in TKO and QKO mESCs
for H3K4me3 and H3K9ac, two chromatin marks associated with
transcriptional activation. We chose these marks on the basis of
their connection to the E2F4 interactome: H3K4 trimethylation is
mediated by the MLL complex, which contains the E2F4
interactors HCF-1 and WDR540; H3K9 acetylation is mediated
by the SAGA complex, which contains TRRAP, and by the ATAC
complex, which contains YEATS2, GCN5, and WDR542. Indeed,
GCN5 and ectopically-expressed E2F4 both associate with MYC
in mESCs48 and we found a significant overlap between GCN5
and E2F4 targets in these cells (Supplementary Fig. 12a).
H3K4me3 and H3K9ac signals showed the expected distribution
around transcriptional start sites (TSS) (Fig. 8a). We observed a
clear decrease of H3K9ac around TSS in QKO compared to TKO
mESCs, while the difference in H3K4me3 signal between QKO
and TKO cells was less apparent (Fig. 8a, b). When compared to
the corresponding peaks in TKO mESCs, a majority of H3K9ac
peaks in QKO mESCs showed a decrease in signal strength
(10008 vs. 676 peaks with increased signal), whereas a majority of
H3K4me3 peaks gained signal (5294 vs. 1679 peaks with
decreased signal) (Fig. 8c, Supplementary Fig. 12b, and
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Fig. 5 Loss of E2F4 leads to defects in the growth of RB family TKO mouse ES cells. a Representative brightfield images (scale bar, 400 µm) and alkaline
phosphatase (AP) staining (wells from a 6-well plate are shown) of RB family triple knockout (TKO) and RB family knockout, E2F4KO (QKO) colonies one
week after plating single cells (n > 10 assays per genotype). b Quantification of the size of AP+ colonies (unpaired t-test; n= 2 biological replicates per
clone). c Total number of cells per 10 cm dish one week after plating at low density (unpaired t-test; n= 2 biological replicates per clone). d Quantification
of the percentage of cells in G1, S, and G2/M phases based on BrdU/PI FACS analysis (unpaired t-test; n= 2–3 biological replicates with 2 TKO and 2 QKO
clones), performed 4 days after low density plating. e Quantification of the percentage of AnnexinVneg/PIneg cells (live cells) in TKO and QKO
populations 4 days after low density plating (unpaired t-test; n= 2 biological replicates per clone). Error bars represent ± s.e.m. Data shown as the mean
and standard error of the mean
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Supplementary Data 9-12). Notably, only 6% and 4% of peaks
that gained signal for H3K4me3 or H3K9ac, respectively, in QKO
mESCs relative to TKO mESCs overlap with TSS (here defined as
−5 kb/+1 kb). In contrast, almost 50% of peaks that lose signal
for H3K4me3 or H3K9ac overlap with TSS (47% and 48%,
respectively).
Collectively, these data suggest that loss of E2F4 is associated
with a global decrease in H3K9ac and H3K4me3 around gene
promoters, consistent with the proposed role of E2F4 as a
transcriptional activator at proximal regulatory regions in mESCs.
Additionally, these data suggest that loss of E2F4 has a greater
impact on H3K9ac rather than H3K4me3 levels, and thus that
histone acetylation may be a more significant contributor to E2F4
activity in mESCs.
When we integrated our ChIP-Seq and RNA-Seq data, we
found that genes that were downregulated upon E2F4 loss show
stronger loss of H3K4me3 and H3K9ac signals than those that
were upregulated (Supplementary Fig. 12c,d). Of these down-
regulated genes, those bound by E2F4 were enriched for genes
with higher H3K9ac levels and slightly higher H3K4me3 levels,
when compared to all downregulated genes or a random set of
downregulated genes (Fig. 8d, e and Supplementary Fig. 12e, f).
Notably, an analysis of the genes associated with decreased
H3K9ac in their promoter region identified an enrichment for
genes bound by E2F4 and cell cycle genes. As few genes were
associated with either increased H3K4me3 or H3K9ac, an
enrichment analysis of these genes yielded very few significantly
(p < 0.05) enriched motifs or pathways (Fig. 8f). These data
suggest that while loss of E2F4 results in a global decrease of
acetylation, this decrease is more significant at direct E2F4 targets,
including cell cycle genes. Taken together with in vitro binding
data and the proteomics analysis, these data support a model in
which E2F4 recruits components of histone acetyltransferase
complexes to mediate transcriptional activation of cell cycle genes
and other E2F targets in mESCs.
Discussion
E2F transcription factors not only regulate the cell cycle in con-
junction with RB family proteins, but also play roles in apoptosis,
differentiation, and stem cell biology that are E2F- and cell type-
specific4,49. Identifying these roles is critical for a better
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understanding of how cell fate decisions are made in development
and misregulated in disease. Here we provide evidence that E2F4
regulates the transcription of a large number of genes in mESCs,
including the activation of cell cycle genes, in a manner that is
largely independent of the RB family. Our studies provide new
insight into the activity of a key E2F family member in a cell type
relevant to development and cancer.
Our data show that E2F4 has functions that are independent of
the RB family. These observations raise several questions,
including how E2F4 is recruited to the nucleus and the DNA.
Ectopic expression of DP-2 and DP-3, which heterodimerize with
E2Fs, can be sufficient to translocate E2F4 to the nucleus17,35,50.
DP-2, which associates with E2F4 in mESCs29 and bears a nuclear
localization signal (NLS)51, may be implicated in E2F4 nuclear
translocation in mESCs. Our data also indicate that E2F4 inter-
acts with proteins involved in nuclear import (KPNB1, RanGAP1,
and RanBP2), which may help promote E2F4 nuclear transloca-
tion in mESCs. Finally, E2F4 harbors a weak putative NLS in
amino acids 52-6151 and E2F4 may translocate into the nucleus in
a cofactor-independent manner, similar to E2F5 during kerati-
nocyte differentiation52. Consistently, our DNA binding domain
mutant, which harbors point mutations within this putative NLS
(R56A and R57A), was unable to translocate into the nucleus. It
will therefore be interesting to examine the subcellular
localization of the N-terminus of E2F4, as well as of different
mutants containing point mutations within and outside the
putative NLS.
E2F4 has a transactivation domain and it is not surprising that
E2F4 activates the transcription of genes once it is bound to
regulatory regions, as shown in overexpression experiments53.
One question remains as to whether E2F4 interacts with the same
transcriptional cofactors as the classical activator E2Fs when it
acts as a transcriptional activator. Our interactome data in TKO
mESCs identified several candidate interactors of E2F4 that
mediate the transcriptional activity of E2F1 to drive diverse
biological processes. These interactors include HCF-1, a compo-
nent of the MLL complex40, as well as TRRAP36,41 and Pontin/
Reptin54. Our analysis of the mass spectrometry data does not
show any post-translational modifications that may mediate
specific binding to these factors. Possibly, these factors bind to
E2F4 in mESCs because the domain of E2F4 normally bound
by the RB family proteins is available for interaction with other
partners. In our interactome analysis, we did not identify Mul-
ticilin or GEMC1, which have been found to function with E2F4
to activate transcription18,19, likely because the genes coding for
these proteins are expressed at a low level in mESCs. Our ChIP-
seq studies strongly suggest that histone acetyltransferase com-
plexes are implicated in E2F4 activity in mESCs. The ATAC and
a b
c Accession # GO term P-value (–log10)
GO:0044427 Chromosomal part
GO:0032991 Macromolecular complex      
18.3788
13.4353
GO:0044424 Intracellular part 11.0726
GO:0043228 Non-membrane-bounded 10.9586
Organelle
GO:0043226 Organelle 10.3354
GO:0071339 MLL1 complex 6.9281
GO:0044464 Cell part 6.383
GO:0005829 Cytosol 6.0953
GO:0032301 MutSalpha complex 4.7399
GO:1902494 Catalytic complex 4.6402
GO:0045120 Pronucleus 3.9547
GO:0097255 R2TP complex 3.7423
GO:0044815 DNA packaging complex      
GO:0032993 Protein-DNA complex 3.3391
GO:0044421 Extracellular region part      
3.3468
3.2314
GO:0048471 Perinuclear region of 3.0448
Cytoplasm
GO:0005844 Polysome 3.0218
GFP TEV S E2F4
Lentiviral infection
into TKO mESCs
and expansion in
roller bottles
1st affinity
purification
GFP TEV S E2F4
Affi-prep
protein A
Anti-GFP
Ab
S E2F4Protein Sagarose
2nd affinity
purification
Interacting
proteins
S E2F4
Wash and
SDS elution
Protein
identification
d
260
160
110
80
60
50
40
30
20
kDa
260
160
110
80
60
50
40
30
20
mESCsRPE
kDa
DP-1 DP-1
E2F4 E2F4
p130
RB
p107
HCFC1
ES
C
RP
E
ES
C
RP
E
Input IP (α-GFP)
E2F4
DP-1
WES
116
66
40
40
66
116
116
180
66
40
40
66
40
66
66
40
66
66
116
116
180
180
116
180
116
180230
116
180
230
66
ES
C
RP
E
ES
C
RP
E
Input IP (α-GFP)
ES
C
RP
E
ES
C
RP
E
Input IP (α-GFP)
HCFC1
LIN54
YEATS2
LIN9
WES WES
Fig. 7 Transcriptional activation by E2F4 in mouse ES cells is mediated by chromatin modifiers. a Schematic representation of the affinity purification-mass
spectrometry approach to identify the E2F4 interactome. b Silver stain of eluted fractions from RPE cells and mouse ES cells . Slices of gel were subjected to
mass spectrometry, and the indicated protein bands were identified by analyzing the proteins enriched in each slice. c GO terms for cellular components
enriched in the list of mouse ES cell-specific candidate interactors. d Validation of interactions between GFP-E2F4 and DP-1, HCFC1, YEATS2, LIN54, and
LIN9, by co-immunoprecipitation followed by immunoassay, in mouse ES cells and human RPE cells. Transcriptional activators (HCFC1 and YEATS2)
preferentially bind to E2F4 in mouse ES cells while members of the DREAM repressor complex (LIN54 and LIN9) bind preferentially to E2F4 in RPE cells.
Molecular weights (kDa) are indicated on the left side (one experiment shown of at least two experiments)
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10901-x ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2939 | https://doi.org/10.1038/s41467-019-10901-x | www.nature.com/naturecommunications 9
SAGA complexes deposit H3K9ac and together contain several
candidate E2F4 interactors, including TRRAP and GCN5, which
are required for E2F transcriptional activity in other contexts55.
Our in vitro binding data demonstrate that the E2F4 transacti-
vation domain can directly bind to the TAZ1 domain of CBP,
suggesting that CBP and/or p300 may also play a role in E2F4-
dependent gene activation in some contexts. Thus, factors
involved in histone acetylation may be critical partners of E2F4 in
the activation of gene programs.
Our gene expression data and rescue experiments also support
the idea that E2F4 may act as a transcriptional repressor even in
the absence of RB, p107, and p130. Repressors such as
TRIM2828,56 may contribute to this repression activity. Because
E2F4 is an ancestral E2F and is expressed in organisms that have
only one E2F homolog57, this switching between gene activation
and gene repression may have been required for the RB/E2F
pathway to serve many different functions throughout develop-
ment. While E2F5 is also known as a canonical repressor E2F, it
may act as a transcriptional activator in specific contexts20,58.
However, our initial experiments did not identify a key role for
E2F5 in the growth of mESCs, possibly because of lower levels of
expression.
Because the transactivation domain of E2F4 is normally
inhibited upon RB family binding, we speculate that the pro-
proliferative role of E2F4 may be restricted to cell types where the
RB family proteins are inactive, as in rapidly cycling progenitor
cells and cancer cells. Several cancer types exhibit E2F4 amplifi-
cation or overexpression5,14. Expansion of CAG repeats in the
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E2F4 coding sequence is also frequent in tumors with genomic
instability such as colorectal carcinomas, and could be oncogenic
by stabilizing E2F459. E2F4 has also been found with the MYC
transcriptional activator at regulatory regions of genes involved in
cancer development60. In many of these experiments, however, it
has been difficult to determine if the effects observed are a direct
result of gene regulation by E2F4. Our work demonstrates that
E2F4 directly promotes the transcription of key cell cycle genes,
and we show that loss of E2F4 directly affects the proliferation
and survival of mESCs. We note, however, that these pro-
proliferative or pro-tumorigenic effects of E2F4 do not have to be
limited to cell cycle activation. For instance, we observed strong
cytoplasmic expression of E2F4 in mESCs, and it is also possible
that E2F4 has important cytoplasmic functions61.
Our work and other studies support a model in which
E2F4 should not simply be viewed as a repressor of transcription
and cell cycle progression. Future work will be needed to identify
the different protein complexes that E2F4 contributes to and the
plethora of cellular functions that are controlled by this major
E2F family member, including in stem cells and cancer cells.
Methods
Cell culture. RPE-FRT9 cells (originally obtained from ATCC) were cultured in
DMEM/F-12 (Thermo Fisher 12400024) supplemented with 10% FBS (Gemini
100–106), 1XGlutaMax (Thermo Fisher 35050-079) and 100 U/mL penicillin-
streptomycin (Thermo Fisher 15140163).
mESC lines J1 and R1 (originally obtained from the laboratory of Rudolf
Jaenisch, MIT) were maintained feeder-free on 0.2% gelatin-coated (Sigma G9382)
plates in Dulbecco’s modified Eagle’s medium (Gibco SH30243.01) containing 15%
fetal bovine serum (Hyclone SH30071.03; VWR Seradigm 97068-085), MEM non-
essential amino acids (Gibco 11140-050), penicillin-streptomycin-glutamine
(Gibco 10378-016), and 0.1 mM beta-mercaptoethanol (Gibco 21985-023),
supplemented with LIF. TKO mESCs were described in32; an independent TKO
mESC line (derived from E14 mESCs) was a kind gift from the Hein te Riele lab33.
MEFs (mouse embryonic fibroblasts, WT and TKO) were obtained and cultured as
described previously32. Cells were passaged enzymatically using 0.05% Trypsin-
EDTA (Gibco 15400-054). For long-term passaging assays, mESCs were passaged
every other day for 20 passages, plating 3.0 × 105 cells per passage. Growth rate was
calculated for 16 passages.
For low-density assays, single-cell suspensions of 50 mESCs/mL were plated
and cultured up to 1 week. Low-density assays in 2i were performed with media
containing 15% serum supplemented with 0.33 nM PD0325901 (Selleckchem
S1036) and 10 nM CHIR99021 (Selleckchem S2924).
For alkaline phosphatase (AP) staining, plates were fixed with 4%
paraformaldehyde, washed with a citrate solution (1:50 citrate concentrate, Sigma
3861), and incubated for 30 min in the dark in a diazonium salt solution (0.25 mg/
mL Fast Violet B Salt, Santa Cruz sc-215029) containing 1:24 naphthol AS-MX
phosphate alkaline (Sigma 855). The number and size of AP+ colonies were
quantified in FIJI. Giemsa stain (Sigma GS500) was applied at 1:40 in water
according to manufacturer’s instructions.
Cell cycle and cell death assays. For analysis of cell cycle structure, mESCs were
plated at low density for 4 days and pulsed with BrdU for 3 h prior to trypsini-
zation, before BrdU and propidium iodide (PI) staining and analysis. Quantifica-
tion of cell death was performed using AnnexinV-FITC and PI according to the
manufacturer’s instructions (BD Biosciences). Gating is shown in Supplementary
Fig. 13. Cells were quantified with a BD FACSAria™ instrument.
For synchronization in G0, mESCs were plated at 25,000 cells/24-well in media
supplemented with 2i, and treated the next day with Ndiff media supplemented
with 2i, LIF, and the Myc inhibitor 10058-F4 (Sigma F3680), as in ref. 34. After 48 h
of Myc inhibition, media was replaced with Ndiff media containing 2i, LIF, and
DMSO only, and cell cycle kinetics were measured by BrdU/PI analysis.
Gene knockout and overexpression. E2F4 knockout was achieved by expressing
Cas9 and sgRNAs from the pX330-U6-Chimeric_BB-CBh-hSpCas9 vector, a gift
from Feng Zhang (Addgene plasmid #42230). WT mESCs were plated at 2 × 105
cells/6-well and transfected the next day with pX330 (empty or with the cloned
sgRNAs) and pPGK-Puro (Addgene plasmid #11349, a gift from Rudolf Jaenisch)
at a ratio of 9:1, using Lipofectamine 2000 according to manufacturer’s instruc-
tions. After 24 h, puromycin selection was applied at a concentration of 2 µg/mL
and continued for 48 h before cells were plated for single cell cloning. Immunoblots
for E2F4 were performed to verify loss of E2F4 protein in all E2F4KO clones
generated from J1 mESCs (n= 6) and R1 mESCs (n= 2). E2F4KO clones used in
the low-density, cell cycle, cell viability, and RNA-Seq experiments were addi-
tionally subjected to quantitative immunoassay for E2F4 protein and TOPO
sequencing of the targeted alleles. Control clones include mESCs transfected with
Cas9 and sgRNAs that had retained E2F4 protein, as well as mESCs transfected
with Cas9 only (empty pX330 vector). Both types of control clones were used in the
RNA-Seq and long-term passaging experiments, while the remaining experiments
were performed with control clones that had retained E2F4 expression after
transfection with Cas9 and sgRNAs. The 5′-3′ sequences of the oligonucleotides
cloned into pX330 are: E2F4-exon1-forward CACCGAGGTCAAGCACGCCG
TCCT, E2F4-exon1-reverse AAACAGGACGGCGTGCTTGACCTC, E2F4-exon3-
forward CACCGCAGCAACGAGAGCAAGAAC, E2F4-exon3-reverse AAACGT
TCTTGCTCTCGTTGCTGC.
E2F4 knockout in TKO mESCs was achieved similarly with the same sgRNAs
by transfecting TKO mESCs (E14) with pX330 and pTracer-CMV/Bsd/lacZ as
above and performing selection with blasticidin at a concentration of 10 µg/mL.
Controls were TKO mESCs transfected with Cas9 and sgRNAs that had retained
E2F4 protein.
A similar strategy was used to knock out E2F1 using the following
oligonucleotides: E2F1-exon1-forward CACCGCGGTGCACTAGGCGCGGGT,
E2F1-exon1-reverse AAACACCCGCGCCTAGTGCACCGC, E2F1-exon1-
forward2 CACCGCAGCACGTCAGAATCGCGA, E2F1-exon1-reverse2
AAACTCGCGATTCTGACGTGCTGC.
For the rescue experiments, vectors expressing GFP, GFP-E2F4, GFP-DBDm,
and GFP-T360 were constructed by cloning cDNAs into the PiggyBac vector, PB-
EF1α-MCS-IRES-GFP with a puromycin resistance gene (a kind gift from Joanna
Wysocka). Correct insertion was validated using the Zero Blunt TOPO PCR
cloning kit (Thermo Fisher K280020) according to manufacturer’s instructions and
Sanger sequencing. WT and E2F4KO mESCs (R1) were transfected with each
rescue vector and PiggyBac transposase at a ratio of 9:1 using Lipofectamine 2000,
and puromycin selection was applied at 2 µg/mL.
Vectors expressing 3xFLAG-tagged E2F4 (FLAG-WT), the two mutant versions
of E2F4 harboring point mutations in the HCF-1 and RB binding domains (FLAG-
HCFC1m and FLAG-RBm), and truncated E2F4 (FLAG-T360) were ordered from
VectorBuilder. The design of FLAG-HCFC1m was based on a previous study40.
The design of FLAG-RBm was based on the same study40 which showed that E2F4
contains one interaction domain mediating binding to HCF-1 and one mediating
binding to RB; and on a study which showed that the RB family binding domain is
conserved across the E2Fs and that mutating D423 and F425 in human E2F1
abolishes binding of E2F1 to RB43. Accordingly, the homologous residues in mouse
E2F4 (D401 and F403), and one additional residue in the RB binding domain
(D404) were mutated to alanines without touching the HCF-1 binding domain.
Embryoid body assay. mESCs were resuspended in media without LIF at a
dilution of 1.0 × 105 cells/mL, and 20 μL drops of the suspension were plated on the
lids of petri dishes filled with phosphate-buffered saline. After three days, retinoic
acid (Sigma R2625) was added to the drops at a final concentration of 0,5 µM and
EBs were grown for another three days. EBs were then plated onto gelatinized
coverslips in media without LIF for 7 days, fixed in 4% paraformaldehyde, per-
meabilized in 0.4% Triton X-100, and blocked in 50 mM glycine. After incubation
with a Tuj1 antibody (BioLegend 802001) overnight, samples were washed, incu-
bated with secondary antibody (Invitrogen Alexa Fluor 594) and counterstained
with DAPI. Images were acquired on a Keyence BZ-X710 fluorescence microscope.
Teratoma assay. Mice were maintained under the care of the Stanford Veterinary
Services Center. All animal studies were approved by the Administrative Panel on
Laboratory Animal Care at Stanford University. All relevant ethical regulations for
animal testing and research were complied with. For each WT and E2F4KO mESC
line, two replicates of 1.0 × 106 cells were mixed with Matrigel and subcutaneously
inoculated into the flanks of NOD scid gamma mice (The Jackson Laboratory
#5557). Teratomas were collected after one week and fixed in 4% formaldehyde,
and H&E staining was performed on sections. Histopathological analysis was
performed by a certified pathologist (H.V.).
Protein purification and protein-protein interactions. The human E2F4 trans-
activation domain (residues 390–407) was expressed in E. coli as an N-terminal
GST fusion protein with a TEV cleavage site and purified, as previously descri-
bed62. Mouse CBP TAZ1 (residues 340–439) was expressed in E. coli with a His-
Nus-XL affinity tag. The TAZ1 domain was purified using nickel affinity resin
followed by tag cleavage and further purification with Superdex 75 size exclusion
chromatography. Equilibrium dissociation constants for binding were obtained
using isothermal titration calorimetry (ITC) with a MicroCal VP-ITC system. Both
E2F4 and CBP proteins were run over Superdex-75 into a buffer containing 25 mM
HEPES pH 7.0, 200 mM NaCl, and 5% glycerol v/v. E2F4 TAD (300 µM) was
titrated into TAZ1 (30 µM) at 25 °C. Data were fit using the MicroCal Origin
analysis package. The concentration of the E2F4 peptide was adjusted such that the
binding stoichiometry (N) was close to 1. We chose this approach of assuming the
stoichiometry because we otherwise noticed unrealistic variability in the N value,
which we attribute to difficulty measuring the E2F4 concentration accurately from
its low extinction coefficient.
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Protein analysis. For detection of protein in whole cell lysates by quantitative
immunoblot, cell pellets were prepared as described previously32, and samples were
run on the WES (ProteinSimple) according to the manufacturer’s protocol. For
fractionation experiments, cells were resuspended at 1 × 108 cells/mL of buffer A
and Triton X-100 was added at 0.1% final concentration. The cells were incubated
on ice for 10 min, the nuclei were collected by centrifugation, and the supernatant
was clarified by high-speed centrifugation. The nuclei were washed once in buffer
A and lysed for 30 min with an equivalent volume of buffer B, and the nuclear
fraction was subjected to 10 rounds of sonication (30 s ON 30 s OFF) to fragment
the genomic DNA. 4 µL per cytoplasmic and nuclear fraction were loaded per lane
of the WES. Co-immunoprecipitation was performed using the GFP-Trap system
developed by ChromoTek (gta-10) according to manufacturer’s instructions. TKO
mESCs were transfected with either the GFP or the GFP-WT vector as above, and
5.0 × 106 cells were used per pull-down. The following antibodies were used: β-
tubulin (Developmental Studies Hybridoma Bank E7), Lamin B1 (D4Q4Z, Cell
Signaling 12586), E2F4 (4E2F04, Thermo Fisher MA1-26624), GFP (rabbit, Invi-
trogen A-11122 and mouse, Santa Cruz sc-57587), DP-1 (TFD10, Santa Cruz sc-
53642), HCFC1 (Novus Biologicals NB100-68210), YEATS2 (Thermo Fisher PA5-
36939), and LIN54 and LIN9 (gift from Dr. Larisa Litovchick). Uncropped images
are provided in the Source Data File.
For visualization of GFP in cell lines that express rescue constructs, 0.2 × 106
cells per line were plated onto a gelatinized 35 mm glass bottom dish (Ibidi 81218),
and live cell imaging of dishes was performed 24 h later on a Zeiss LSM5 10 Meta
Confocal Microscope.
RT-qPCR and RNA-Seq. All gene expression analyses were performed on cells
grown at low density for four days and RNA extraction was performed using the
RNeasy micro kit (Qiagen 74004). For RT-qPCR, complementary DNA (cDNA)
was synthesized using the ProtoScript First Strand cDNA Synthesis Kit (E6300)
and qPCR was performed using the SYBR GreenER Master Mix (Invitrogen) on an
ABI 7900HT Detection System, with primers listed in Supplementary Data 13. All
samples were run in triplicate and normalized to a Gapdh RT-qPCR. For RNA-Seq,
libraries were prepared using the TruSeq Stranded mRNA Library Preparation Kit
(Illumina RS-122-2101). Four wild-type and four E2F4KO mESC lines were
sequenced on a HiSeq4000, generating on average 40 million paired-end (2 × 76)
reads per sample. Similarly, two passages of two TKO and two QKO lines were
sequenced on a separate run of a HiSeq4000, generating on average 45 million
paired-end (2 × 76) reads per sample. Obtained reads were mapped to mouse
reference genome mm10 with STAR2.5.1b using default settings with an average
mapping rate of 96% (73% to genes). Genes that had at least ten reads in two out of
four samples of either the control group or the experimental group were used for
further analysis. Differentially expressed genes were obtained using DEseq2.
ChIP-qPCR and ChIP-Seq. Chromatin immunoprecipitation (ChIP) was done
according to a published method63. Briefly, mESCs were crosslinked with 1%
formaldehyde in PBS for 10 min at room temperature and the reaction was stopped
by adding glycine to a final concentration of 1.25 M for 5 min at room temperature.
Crosslinked cells were collected with a cell scraper, rinsed twice with PBS, and
resuspended at a concentration of 5 × 107 cells/mL of swelling buffer (0.1 M Tris
pH 7.6, 10 mM KOAc, 15 mM MgOAc, 1% NP40) to remove the cytoplasmic
fraction. Nuclei were resuspended at a concentration of 10 × 108 cells/mL of nuclei
lysis buffer (50 mM Tris-Cl pH 8.0, 10 mM EDTA, 1% SDS), and lysate was
sonicated for 90 cycles (30 s ON/50 s OFF) in a Diagenode Bioruptor (Diagenode
UCD-300). The sonicated chromatin was pre-cleared by adding washed and
blocked StaphA at a concentration of 10 µL/1 × 107 cells (Calbiochem 507862).
StaphA were washed in dialysis buffer (2 mM EDTA, 50 mM Tris-Cl pH 8.0), and
blocked in 10 mg/mL salmon sperm DNA (EMD Millipore 16–157) and 10 mg/mL
BSA. For each IP, 100 µL of pre-cleared chromatin was diluted in twice the volume
of IP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM
Tris–HCl pH 8.0, 167 mM NaCl) and 5 µg of antibody was added. Antibodies
against E2F4 (C-20, Santa Cruz sc-866X), H3K4me3 (Abcam ab8580) and H3K9ac
(Active Motif 39137) were used. IP and 10% input samples were rotated overnight
at 4 °C and pull-down was performed with washed/blocked StaphA at a con-
centration of 10 µL/IP. StaphA pellets were washed twice with dialysis buffer, then
four times with IP wash buffer (100 mM Tris–Cl pH 9.0, 500 mM LiCl, 1% NP40,
1% Deoxycholic Acid). IP elution buffer (50 mM NaHCO3, 1% SDS) was added
and samples were vortexed to release protein/DNA complexes from StaphA.
Crosslinks were reversed by incubation in elution buffer+ 0.2 M NaCl at 67 °C for
4 h. Sonicated DNA was purified using the Qiagen QIAquick PCR purification kit
(Qiagen 28104). ChIP-qPCR was performed using the SYBR GreenER Master Mix
(Invitrogen) on an ABI 7900HT Detection System, with primers listed in Sup-
plementary Data 13.
For ChIP-Seq, libraries of two biological replicates (at different passages) of two
TKO clones (TKO2 and TKO3 in Fig. 5) and two QKO clones (QKO1 and QKO2
in Fig. 5). ChIP for H3K4me3 and H3K9ac and corresponding input samples were
constructed using the NEBNext DNA Sample Prep Master Mix Set for Illumina
(NEBNext E6040) and NEBNext Multiplex Oligos for Illumina (NEBNext E7335
and E7500) according to kit instructions. Libraries were quantified using the KAPA
Library Quantification Kit with Universal qPCR Master Mix (KAPA Biosystems,
KK4824) according to kit instructions, qPCR was performed using the SYBR
GreenER Master Mix (Invitrogen) on an ABI 7900HT Detection System, and
pooled samples were sequenced on a HiSeq4000, generating on average 23 million
single-end reads per sample. Obtained reads were mapped to mouse reference
genome mm9 with bowtie2.3.4. Peakcalling was performed with MACS2.1.1 using
broadpeaks, merging the two replicates from identical cell lines, and using the
merged input samples as control. Differential peaks were determined with the R
package DiffBind (https://bioconductor.org/packages/release/bioc/html/DiffBind.
html), again merging the two replicates from identical cell lines and using the peaks
generated by MACS. Deeptools was used to visualize the data64. For enrichment
analysis, genes associated with the peaks were identified by mapping the peaks to
the nearest transcription start sites (within 5.0 kb upstream and 1.0 kb
downstream) using GREAT.
E2F4-bound genes were obtained from publically available .bed files
(GSE48666), by peak calling with MACS and remapping the peaks to the nearest
transcription start sites (within 1.0 kb upstream and 1.0 kb downstream) using
GREAT65.
Tandem affinity purification and mass spectrometry. Tagged mouse E2F4 was
overexpressed in TKO mESCs by lentiviral infection. The lentiviral backbone
vector (pWPXLd/LAP-C/puro/DEST) was created by inserting a DEST/TEV
cleavage site-S tag-PreScission cleavage site-EGFP/puromycin resistance cassette
into pWPXLd vector (a gift from Didier Trono, Addgene plasmid #12258). The
Gateway entry vector for mouse E2F4 was generated by cloning E2F4 cDNA from
the PiggyBac system into pDONR221. Then the N-terminally LAP (EGFP-TEV
cleavage site-S tag-PreScission cleavage site)-tagged mouse E2F4 was generated by
LR recombination between E2F4 entry vector and pWPXLd/LAP-N/puro/DEST.
Lentiviral infection was performed, as described in ref. 66. Following infection for
48 h, GFP-positive cells were isolated by fluorescent-activated cell sorting with a
BD FACSAria™ instrument.
Tagged human E2F4 was overexpressed in RPE cells using the Flp-In system.
Gateway entry vector for human E2F4 was obtained from Life Technologies (clone
number IOH23241). Flp-In system compatible N-terminally LAP (EGFP-TEV
cleavage site-S tag-PreScission cleavage site)-tagged human E2F4 was generated by
LR recombination between the hE2F4 entry vector and pG-LAP6/puro. Flp-In
system compatible RPE cells. RPE cells were transfected with 150 ng of LAP-hE2F4
and 850 ng of pOG44, and selection was performed with 10 µg/mL puromycin.
Tandem affinity purification and analysis were performed as previously
described66,67. The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE68 partner repository with the dataset
identifier PXD008796 and 10.6019/PXD008796.
Statistical analysis. Statistical significance was assayed with GraphPad Prism
software. Data are represented as mean ± SEM. Unless otherwise specified, each
control and experimental line was subjected to at least two biological replicates, and
the average of the biological replicates was recorded and used in the t-test. GO term
enrichment analysis of differentially expressed genes was performed with GOrilla69
and visualization was performed using REVIGO70 to filter out redundant GO
terms. The allowed similarity was decreased to the lowest settings to generate the
smallest list of GO terms per set of genes. Unpaired t-tests were performed with all
individual data points from all the biological replicates. P-values for overlap in
Venn diagrams were obtained using the hypergeometric test.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data generated or analyzed during this study are included in this published article and
its supplementary information files or are available from the corresponding author upon
reasonable request. RNA-seq and ChIP-seq data are available in the ‘GEO repository’
under the accession number GSE109684. Proteomics datasets are available in the ‘EBI
repository’ under the accession number PXD008796. Raw data underlying all Figures are
provided as a Source Data file. A reporting summary for this Article is available as
a Supplementary Information file.
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